Israel is one of the most consequential cannabis markets in the world relative to its size. It legalised medical use early, built a world-leading research base, and developed one of the largest per-capita licensed-patient populations anywhere — yet it remains overwhelmingly supplied by an illicit market, leans heavily on imported flower, and is in the middle of a contested regulatory overhaul. This page is a standing overview, refreshed as the numbers and rules change.
A medical market, not a recreational one
Adult-use cannabis is not legal in Israel. The regulated market is strictly medical, accessed through a Ministry of Health licence or, increasingly, a prescription routed through the public health funds. By revenue, the Israeli cannabis market is projected to reach roughly US$372 million in 2025, a meaningful figure for a country of about 9.8 million people.
The defining feature of the market is the gap between legal and illicit consumption. Industry estimates put illicit users in the low millions — around 2.4 million estimated illicit users against roughly 132,800 legal medical patients in 2025 — meaning the regulated channel serves well under 10% of actual consumption. Closing even a fraction of that gap is the long-term growth thesis for every licensed operator in the country.
A decade of expansion, then the first decline
For more than ten years, the licensed patient base grew almost without interruption. A peer-reviewed review of Health Ministry data published in the Journal of Cannabis Research traces the arc precisely: from just 3,097 active licences in April 2011 to 140,483 by January 2024 — an increase of roughly 4,400%.
That trajectory has now broken. Following a 2024 reform that moved prescribing into the health maintenance organisations (HMOs), the same study records the program's first sustained contraction: a 7.5% decline to about 129,900 active licences and prescriptions by March 2025. The researchers attribute the drop to stricter HMO gatekeeping and transition friction, compounded by a cleanup of licences issued under questionable circumstances — in one case, a single physician had reportedly approved more than 13,000 licences before authorisations were revoked. As those licences lapsed, many were not renewed.
The composition of treatment has shifted too. Chronic non-cancer pain remains the dominant indication, rising from 53% to 63% of approvals, while post-traumatic stress disorder grew by roughly 89% — a trend amplified by the war that began in October 2023 and its toll on soldiers and civilians.
Import-dependent supply
Israel grows a substantial share of its own cannabis, but it does not grow enough. Roughly one-third of products consumed are imported, with the balance produced by licensed domestic cultivators. Canada has been the single most important source of imported flower, alongside smaller volumes from Uganda, Ethiopia, Germany and elsewhere. In a single month in 2025, Israeli pharmacies processed upwards of 302,000 approved flower packages.
That import dependence is why trade policy has become a cannabis story (see below), and why flower remains central: dried flower accounted for over 94% of medical cannabis usage by 2025, a fact that makes any regulatory move against smokable formats existential for the supply chain.
Three policy fights shaping 2026
Heading into 2026, three live threads matter more than any others.
1. Tariffs on Canadian imports. Israel's Ministry of Economy, under Minister Nir Barkat, proposed an anti-dumping duty of up to 165% on Canadian cannabis after finding that Canadian producers were exporting below domestic and even below cost. The proposed rates were differentiated by producer — 165% as a default, but lower for some firms (Tilray at 70%, Organigram at 53%, Village Farms at 28%, Decibel at 12%). Finance Minister Bezalel Smotrich blocked the measure, warning it would raise patient prices and feed the black market; backed by legal opinion, the rejection appears to have settled the matter for now, though it could be resubmitted.
2. A smokable-cannabis rollback. A Health Ministry committee led by Dr. Gilad Bodenheimer recommended phasing out smoked medical cannabis over three years, with exceptions only for patients over 75 and the terminally ill, arguing that smoking delivers inconsistent dosing and normalises a psychoactive substance faster than the system can manage. Given that flower dominates usage, the proposal would force a wholesale shift toward oils, extracts and precision inhalers. Health Minister Haim Katz subsequently froze implementation, leaving the question open.
3. The patient-number plateau. The end of a decade of growth changes the calculus for operators. The question is no longer expansion at any cost but margin, format and consolidation — and several Israeli firms have responded by pivoting toward the faster-growing German market.
Why it matters beyond Israel
Israel punches far above its weight on cannabinoid research and clinical credibility, a legacy that runs from Raphael Mechoulam's isolation of THC to the present-day research base. International operators, investors and regulators watch the country as a testbed for medical-cannabis policy. That combination — a small domestic market with outsized scientific and regulatory influence — is the throughline of everything we cover.
Related: Regulation · The major operators · Research legacy · Patient access
Sources include the peer-reviewed Journal of Cannabis Research review (2011–2025), Statista, GrowerIQ, MMJ Daily, StratCann, The Times of Israel and The Marijuana Herald. Figures are refreshed periodically; check linked sources for the latest.
Compiled and reviewed by Tamar Levin, Editor. Sources are linked inline. This page is reviewed and refreshed periodically; it is informational and is not medical or legal advice.